| Meta Platforms [META] - Last Close: $43.53 Facebook parent Meta is moving higher after a strong earnings report. The social media company reported stronger-than-expected figures for earnings and revenues on its Q1 earnings report on Wednesday evening. Meta reported EPS of $2.20 against the consensus of $1.97, and its $28.65 billion revenue figure also topped the Street's $27.66 billion target. The company's advertising revenues also returned to positive growth for the first time in almost a year. The report prompted several analysts to upgrade their ratings on the social media stock. META is the premarket's leading large-cap with a 12.2% gain. My Take: META's chart looks good. This stock has steadily moved higher over the past year, and today's rally could help it enter a new positive-trend phase. Atomera [ATOM] - Last Close: $5.22 Atomera is surging after a recent announcement. The semiconductor equipment developer released its Q1 2023 results on Wednesday, and it unveiled a new deal as part of the release. Atomera said it landed a commercial license agreement with STMicroelectronics for the installation of its Mears Silicon Technology in the company's facilities. The deal also authorizes STMicroelectronics to manufacture and distribute Atomera's MST-enabled products to its customers. News of the deal lifted ATOM to a 34.6% gain in today's premarket. My Take: ATOM's stock has looked better, but it could be in prime position to swing higher if it can keep this momentum going. ContraFect Corp [CFRX] - Last Close: $1.32 ContraFect is up following a clinical update. On Wednesday morning, the biotech firm announced it had dose the first patient in a Phase 1b/2 study of exebacase in prosthetic joint infections of the knee. The randomized, double-blind, placebo-controlled clinical study will examine the drug's safety, pharmacokinetics, and efficacy. The company said it believes the drug can replace expensive surgery and provide better outcomes for patients. CFRX fell 15.3% on Wednesday following this early morning announcement, but its pivoting higher in today's premarket. CFRX is up 57.5% on active trading volume ahead of today's opening bell. My Take: This rally seems out of place. CFRX was down following this news yesterday, but some investors apparently see an opportunity. Evelo Biosciences [EVLO] - Last Close: $0.10 Something weird is going on with Evelo Bio's stock. The biotech firm fell 32.8% on Wednesday after announcing it would shut down its atopic dermatitis study after it missed its primary goal. Evelo said the fourth cohort of its EDP1815 Phase 2 trial missed its primary endpoint, just like the first three cohorts, so the company shuttered the study. The bearish news sent the stock tumbling to a new 52-week low in Wednesday's session. However, shares are suddenly reversing course in today's premarket. EVLO is rebounding from Wednesday's sell off with a 77.9% gain in Thursday's premarket. My Take: I am not sure what's behind EVLO's move, but I am dubious. This looks like a pump-and-dump set up. GainersBitNile Metaverse [BNMV] >> +15.5%Biomx [PHGEI] >> +25.4%U Power [UCAR] >> +17.9%DeclinersBaudax Bio [BXRX] >> (53.3%)Impinj [PI] >> (29.0%)Wolfspeed [WOLF] >> (15.3%) Eli Lilly And Company [LLY] ... AM
Mastercard Incorporated [MA] ... AM
Merck & Company, Inc. [MRK] ... AM
Abbvie Inc. [ABBV] ... AM
Linde Plc [LIN] ... AM
Comcast Corporation [CMCSA] ... AM
Bristol-Myers Squibb Company [BMY] ... AM
Honeywell International Inc. [HON] ... AM
Amazon.Com, Inc. [AMZN] ... PM
T-Mobile Us, Inc. [TMUS] ... PM GDP [Q1] ... 8:30a Weekly jobless claims ... 8:30a Pending home sales [Mar] ... 10:00a | 